Growth factors play a crucial role in the pathomechanism of pulmonary arterial hypertension and may serve as potential cardioprotective biomarkers and novel therapeutic targets.
Growth factors play a significant role in the pathophysiology of PAH and may serve as potential cardioprotective biomarkers and therapeutic targets for preserving right ventricular function.
Pulmonary arterial hypertension (PAH) is a rare and progressive disease, characterized by increased vascular resistance leading to right ventricle (RV) failure. The extent of right ventricular dysfunction crucially influences disease prognosis; however, currently no therapies have specific cardioprotective effects. Besides discussing the pathophysiology of right ventricular adaptation in PAH, this review focuses on the roles of growth factors (GFs) in disease pathomechanism. We also summarize the involvement of GFs in the preservation of cardiomyocyte function, to evaluate their potential as cardioprotective biomarkers and novel therapeutic targets in PAH.
Csósza et al. (Mon,) conducted a review in Pulmonary arterial hypertension. Growth factors was evaluated. Growth factors play a crucial role in the pathomechanism of pulmonary arterial hypertension and may serve as potential cardioprotective biomarkers and novel therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: